Document › Details
Bruker Corporation. (10/29/10). "Press Release: National High Magnetic Field Laboratory at Florida State University Selects Bruker to Build World’s First 21.0 Tesla FT-ICR Magnet". Cambridge, MA.
|Country||United States (USA)|
|Organisation||Bruker Daltonics (Operating Business of Bruker Corporation)|
|Group||Bruker Corporation (Group)|
|Organisation 2||Florida State University, National High Magnetic Field Laboratory (NHMFL)|
|Group||Florida State University (FSU)|
|Product 2||FTICR-MS (Fourier transform ion cyclotron mass spectrometer)|
|Index term 2||Florida State Univ–United States (govt): grant, 201006 NSF grant of $17.5m for 21-tesla magnet to National High Magnetic Field Laboratory|
|Person||Marshall, Alan G. (Florida State Univ 201003 Professor + National High Magnetic Field Labaoratory Director ICR Program)|
|Person 2||Roth, Gerhard (Bruker 200903 Managing Director of Bruker BioSpin)|
Bruker Daltonics today announced that the National High Magnetic Field Laboratory (NHMFL) at Florida State University has selected Bruker to design and build the world's first 21.0 tesla (T) Fourier Transform Ion Cyclotron Resonance (FT-ICR) magnet. The magnet will be designed in collaboration with NHMFL scientists and used in the FT-ICR program at the lab. The contract for the magnet is valued at over $10 million, the project is funded by the National Science Foundation, and delivery of the magnet is planned for the first half of calendar year 2013.
FT-ICR is the highest resolution mass spectrometer available and is useful in the analysis of extremely complex mixtures, including petroleum, metabolites, and for the characterization of large biological molecules such as proteins. The performance of FT-ICR systems improves with increasing magnetic field, and the highest field systems currently available operate at 15 T, so the 21.0 T system represents a dramatic improvement of 40% in mass resolution, and more than 90% in mass accuracy over currently available systems. The ICR program at the NHMFL leads the world in instrument and technique development as well as in pursuing novel applications of FT-ICR mass spectrometry.
Bruker Corporation (NASDAQ: BRKR) is a global leader in the development and supply of complete high-performance FT-ICR (or FTMS) mass spectrometers, and also in the development and supply of ultra-high field superconducting magnets for NMR, EPR, preclinical MRI and FT-ICR. Its subsidiary Bruker Energy & Supercon Technologies, Inc. (BEST) is a recognized leader in the development and supply of the specialized superconductors used in ultra-high field magnets. Bruker Corp. has already ordered the superconducting wire from BEST to meet the ambitious delivery schedule of the NHMFL 21 T FT-ICR magnet project.
Professor Alan Marshall, Robert O. Lawton Professor of Chemistry and Biochemistry at Florida State University and Director of the high field FT-ICR program at the NHMFL commented: "The delivery of the 21.0 T FT-ICR magnet from Bruker, together with instrumentation developments we have planned, will lead to revolutionary new capabilities in FT-ICR, by significantly extending current upper limits for macromolecular weight, as well as chemical complexity. We are confident in Bruker's ability to build and deliver this first-in-class magnet, and look forward to working with their team of experts on the design of the FT-ICR system for use with the magnet."
Dr. Chris Hendrickson, Director of Instrumentation for the high field FT-ICR program, stated: "In addition to important applications in biomedical sciences, we view the study of petroleum as one of the most important applications for the new instrument. As the world's supply of light sweet crude is exhausted and we turn to heavier sources of crude to meet our energy needs, the feedstock for refineries that produce fuel will become even more complex. To ensure the most efficient processing of these feedstocks into fuel that burns cleanly, an understanding of the nature of the feedstocks at a molecular level will be important. FT-ICR is the only mass spectrometric technique capable of completely resolving all of the molecular components of petroleum. The new 21.0 T FT-ICR system will be an important facility for research that will support the reliable production of clean burning petroleum products in the future."
The 21.0 T magnet design offers a 110 mm room temperature horizontal bore, and includes many design features pioneered by Bruker. These include operation at a temperature of ~2 Kelvin by use of Bruker's unique UltraStabilized(TM) cooling technology, the UltraShield(TM) technology which reduces magnetic stray fields, and makes the use of such magnets possible in a routine environment, as well as active magnet refrigeration technology that virtually eliminates user maintenance of the magnet.
Dr. Gerhard Roth, the Bruker Corporation Ultra-High Field Magnet Manager, said: "We are extremely pleased and honored to have been selected to build the world's first horizontal bore 21.0 T magnet for FT-ICR. While this magnet advances the envelope of current technology, we have a successful track record of delivering systems of similar complexity in order to enable novel science."
Dr. Klaus Schlenga, the Chief Technology Officer of BEST, added: "We are also proud to be part of this exciting project as the manufacturer of the core metallic superconductors for this novel 21.0 T FT-ICR magnet. We endeavour to supply high quality and performance NbTi and Nb3Sn superconductors produced using our proprietary bronze-route process, which we manufacture already for some of the most demanding ultra-high field NMR and MRI magnets."
For more information about the High-Field FT-ICR program at the NHMFL, please visit http://www.magnet.fsu.edu/usershub/scientificdivisions/icr.
ABOUT BRUKER DALTONICS
For more information about Bruker Daltonics and Bruker Corporation, please visit http://www.bdal.com and http://www.bruker.com.
CAUTIONARY STATEMENT OF BRUKER CORPORATION
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2009, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Gary H. Kruppa, Ph.D., +1 925-337-0835
Vice President, Business Development
Record changed: 2016-03-19
More documents for Bruker Corporation (Group)
-  Bruker Corporation. (1/4/17). "Press Release: Bruker Announces Acquisition of CMO InVivo Biotech to Expand Molecular Biology, Microbiology and Pathology Consumables and Assay Business". Berlin....
-  Bruker Corporation. (1/4/17). "Press Release: Bruker Announces Acquisition of SCiLS GmbH to Advance MALDI Imaging Software Solutions for Life Science, Pharma and Pathology Research Applications". Bremen....
-  Bruker Corporation. (1/3/17). "Press Release: Bruker Corporation to Present at the 35th Annual J.P. Morgan Healthcare Conference". Billerica....
-  Bruker Corporation. (12/21/16). "Press Release: Bruker Delivering 300 Hand-held Chemical Detectors to German BBK". Leipzig....
-  Bruker Corporation. (12/16/16). "Press Release: Bruker Announces Acquisition of Active Spectrum Micro-ESR Business". Billerica, MA....
-  Bruker Corporation. (12/2/16). "Press Release: Bruker Announces Corporate Partnership with International Phenome Centre Network (IPCN) for NMR Technologies and SOPs". Billerica, MA....
-  Bruker Corporation. (11/28/16). "Press Release: Bruker AXS Introduces a New Member to the D8 ADVANCE Family — the D8 ADVANCE Plus". Boston, MA....
-  Bruker Corporation. (11/22/16). "Press Release: Bruker Completes Acquisition of Preclinical PET Imaging Business". Billerica, MA....
-  Bruker Corporation. (11/17/16). "Press Release: Bruker and Oxford Instruments Announce Acquisition of Oxford Instruments Superconducting Wire Business by Bruker's BEST Segment". Billerica, MA & Tubney Woods....
-  Bruker Corporation. (11/16/16). "Press Release: Cetim Facility Receives Bruker Contour CMM Dimensional Analysis System". San José, CA & Senlis....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]